Evotec SE (NASDAQ:EVO) Short Interest Up 42.0% in September

Evotec SE (NASDAQ:EVO) saw a large increase in short interest in September. As of September 15th, there was short interest totalling 271,800 shares, an increase of 42.0% from the August 31st total of 191,400 shares. Currently, 0.1% of the company’s stock are short sold. Based on an average daily volume of 83,900 shares, the short-interest ratio is presently 3.2 days.

Evotec Price Performance

NASDAQ:EVO traded up $0.08 during trading hours on Friday, hitting $3.57. The company’s stock had a trading volume of 116,721 shares, compared to its average volume of 107,509. The stock has a fifty day simple moving average of $3.68 and a 200-day simple moving average of $5.02. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.73 and a current ratio of 1.83. Evotec has a twelve month low of $2.85 and a twelve month high of $12.00.

Institutional Trading of Evotec

Several large investors have recently bought and sold shares of the business. Vanguard Personalized Indexing Management LLC bought a new position in Evotec in the second quarter valued at about $87,000. Cetera Advisors LLC bought a new position in Evotec in the first quarter valued at about $188,000. DCF Advisers LLC raised its position in Evotec by 140.5% in the second quarter. DCF Advisers LLC now owns 114,953 shares of the company’s stock valued at $552,000 after purchasing an additional 67,156 shares during the last quarter. Optiver Holding B.V. raised its position in Evotec by 643.1% in the fourth quarter. Optiver Holding B.V. now owns 80,810 shares of the company’s stock valued at $945,000 after purchasing an additional 69,936 shares during the last quarter. Finally, Mubadala Investment Co PJSC bought a new position in Evotec in the fourth quarter valued at about $53,931,000. 5.81% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of brokerages have commented on EVO. Morgan Stanley lowered Evotec from an “overweight” rating to an “equal weight” rating and decreased their price objective for the company from $15.00 to $6.00 in a report on Monday, July 29th. Deutsche Bank Aktiengesellschaft lowered Evotec from a “hold” rating to a “sell” rating in a report on Thursday, August 8th. Finally, HC Wainwright reduced their target price on Evotec from $11.00 to $8.00 and set a “buy” rating on the stock in a report on Thursday, August 15th.

Evotec Company Profile

Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women's health.